190 related articles for article (PubMed ID: 35514958)
21. Proteomic analysis of lysine 2-hydroxyisobutyryl in SLE reveals protein modification alteration in complement and coagulation cascades and platelet activation Pathways.
Kuang C; Li D; Zhou X; Lin H; Zhang R; Xu H; Huang S; Tang F; Liu F; Tang D; Dai Y
BMC Med Genomics; 2023 Oct; 16(1):247. PubMed ID: 37845672
[TBL] [Abstract][Full Text] [Related]
22. Proteomic analysis of human plasma and peripheral blood mononuclear cells in Systemic Lupus Erythematosus patients.
Pinna S; Pasella S; Deiana M; Baralla A; Mannu A; Masala AGE; Pileri PV; Deiana N; Scognamillo F; Pala C; Zinellu A; Carru C; Deiana L
J Immunol Methods; 2017 Jul; 446():37-46. PubMed ID: 28390925
[TBL] [Abstract][Full Text] [Related]
23. Lipidomic and metabolomic profiling reveals novel candidate biomarkers in active systemic lupus erythematosus.
Li Y; Liang L; Deng X; Zhong L
Int J Clin Exp Pathol; 2019; 12(3):857-866. PubMed ID: 31933894
[TBL] [Abstract][Full Text] [Related]
24. Serum metabolomic profiling in patients with systemic lupus erythematosus by GC/MS.
Yan B; Huang J; Zhang C; Hu X; Gao M; Shi A; Zha W; Shi L; Huang C; Yang L
Mod Rheumatol; 2016 Nov; 26(6):914-922. PubMed ID: 26915395
[TBL] [Abstract][Full Text] [Related]
25. Whole Blood and Plasma-Based Lipid Profiling Reveals Distinctive Metabolic Changes in Systemic Lupus Erythematosus and Systemic Sclerosis.
Ferreira HB; Melo T; Guerra IMS; Moreira ASP; Laranjeira P; Paiva A; Goracci L; Bonciarelli S; Domingues P; Domingues MR
J Proteome Res; 2023 Sep; 22(9):2995-3008. PubMed ID: 37606915
[TBL] [Abstract][Full Text] [Related]
26. Downregulated miR‑29a promotes B cell overactivation by upregulating Crk‑like protein in systemic lupus erythematosus.
Shi X; Ye L; Xu S; Guo G; Zuo Z; Ye M; Zhu L; Li B; Xue X; Lin Q; Ding X
Mol Med Rep; 2020 Aug; 22(2):841-849. PubMed ID: 32467986
[TBL] [Abstract][Full Text] [Related]
27. Adipokine interactions promote the pathogenesis of systemic lupus erythematosus.
Chougule D; Nadkar M; Venkataraman K; Rajadhyaksha A; Hase N; Jamale T; Kini S; Khadilkar P; Anand V; Madkaikar M; Pradhan V
Cytokine; 2018 Nov; 111():20-27. PubMed ID: 30098476
[TBL] [Abstract][Full Text] [Related]
28. Polyamine patterns in plasma of patients with systemic lupus erythematosus and fever.
Kim HA; Lee HS; Shin TH; Jung JY; Baek WY; Park HJ; Lee G; Paik MJ; Suh CH
Lupus; 2018 May; 27(6):930-938. PubMed ID: 29308729
[TBL] [Abstract][Full Text] [Related]
29. Single-cell multi-omics analysis reveals IFN-driven alterations in T lymphocytes and natural killer cells in systemic lupus erythematosus.
Trzupek D; Lee M; Hamey F; Wicker LS; Todd JA; Ferreira RC
Wellcome Open Res; 2021; 6():149. PubMed ID: 35509371
[No Abstract] [Full Text] [Related]
30. NovelmiRNA-25 inhibits AMPD2 in peripheral blood mononuclear cells of patients with systemic lupus erythematosus and represents a promising novel biomarker.
Guo G; Wang H; Shi X; Ye L; Wu K; Lin K; Ye S; Li B; Zhang H; Lin Q; Ye S; Xue X; Chen C
J Transl Med; 2018 Dec; 16(1):370. PubMed ID: 30577810
[TBL] [Abstract][Full Text] [Related]
31. Increased oxidative stress contributes to impaired peripheral CD56
Lu Z; Tian Y; Bai Z; Liu J; Zhang Y; Qi J; Jin M; Zhu J; Li X
Arthritis Res Ther; 2022 Feb; 24(1):48. PubMed ID: 35172900
[TBL] [Abstract][Full Text] [Related]
32. Metabolic Profiling of Systemic Lupus Erythematosus and Comparison with Primary Sjögren's Syndrome and Systemic Sclerosis.
Bengtsson AA; Trygg J; Wuttge DM; Sturfelt G; Theander E; Donten M; Moritz T; Sennbro CJ; Torell F; Lood C; Surowiec I; Rännar S; Lundstedt T
PLoS One; 2016; 11(7):e0159384. PubMed ID: 27441838
[TBL] [Abstract][Full Text] [Related]
33. Expression of human T cell immunoglobulin domain and mucin-3 (TIM-3) and TIM-3 ligands in peripheral blood from patients with systemic lupus erythematosus.
Jiao Q; Qian Q; Zhao Z; Fang F; Hu X; An J; Wu J; Liu C
Arch Dermatol Res; 2016 Oct; 308(8):553-61. PubMed ID: 27394439
[TBL] [Abstract][Full Text] [Related]
34. Elevated semaphorin5A in systemic lupus erythematosus is in association with disease activity and lupus nephritis.
Du Y; Wu X; Chen M; Wang W; Xv W; Ye L; Wu D; Xue J; Sun W; Luo J; Wu H
Clin Exp Immunol; 2017 May; 188(2):234-242. PubMed ID: 28063160
[TBL] [Abstract][Full Text] [Related]
35. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
36. ¹H NMR-based metabolomic study of metabolic profiling for systemic lupus erythematosus.
Ouyang X; Dai Y; Wen JL; Wang LX
Lupus; 2011 Nov; 20(13):1411-20. PubMed ID: 21976403
[TBL] [Abstract][Full Text] [Related]
37. Potential Involvement of Platelet-Derived Microparticles and Microparticles Forming Immune Complexes during Monocyte Activation in Patients with Systemic Lupus Erythematosus.
Burbano C; Villar-Vesga J; Orejuela J; Muñoz C; Vanegas A; Vásquez G; Rojas M; Castaño D
Front Immunol; 2018; 9():322. PubMed ID: 29545790
[TBL] [Abstract][Full Text] [Related]
38. Immunometabolomics provides a new perspective for studying systemic lupus erythematosus.
Wu Y; Zhao M; Gong N; Zhang F; Chen W; Liu Y
Int Immunopharmacol; 2023 May; 118():109946. PubMed ID: 36931174
[TBL] [Abstract][Full Text] [Related]
39. PGLYRP2 as a novel biomarker for the activity and lipid metabolism of systemic lupus erythematosus.
Li H; Meng D; Jia J; Wei H
Lipids Health Dis; 2021 Aug; 20(1):95. PubMed ID: 34461924
[TBL] [Abstract][Full Text] [Related]
40. Immunometabolism in systemic lupus erythematosus: Relevant pathogenetic mechanisms and potential clinical applications.
Tzeng HT; Chyuan IT
J Formos Med Assoc; 2021 Sep; 120(9):1667-1675. PubMed ID: 33836940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
